Funded Projects › FP7
NOVO · Novel approaches for prevention and degeneration of pathogenic bacteria biofilms formed on medical devices e.g. catheters
Biofilms are bacterial communities encased in a self-produced hydrated polymeric matrix. An important characteristic of microbial biofilms is their innate resistance to the immune system and susceptibility to antibiotics. This resistance has made microbial biofilms a common cause of medical infections, and difficult-to-treat infections caused by colonized foreign bodies.The NOVO project aims at developing novel approaches to prevent and/or degrade biofilms on catheters elongating their usage in humans up to 10 days.Two complementary approaches for biofilm prophylaxis will be developed:A. Ultrasonic coating of Inorganic antibiofouling agents (process developed by partner BIU) based on a single step sonochemical process to: a) Produce metal fluorides or metal oxides (e.g. MgF2, ZnO) nanoparticles (NPs) and simultaneously b) Impregnate them as antibacterial factors on the catheters. c) Co-coating with bio-inert polymer layers (containing highly hydrophilic antifouling polyethylene glycol, zwitterionic moieties or sugar-groups) grafted onto NPs of adjusted size to the size of MgF2/ZnO NPs or directly onto MgF2/ZnO NPs; to form a hydrogel layer for the protection of the MgF2/ZnO antibiofouling activity.B. Bio/organic antibiofouling activation: 1) Novel coating for catheters based on radical catalyzed polymers to yield anti-bacterial activity. An enzymatic reaction will be applied on the phenolic compounds to generate phenolic radicals to be further polymerized on the catheter surface as an antibiofilm agent. 2) Develop and engineer Cellobiose Dehydrogenases (CDH) that actively oxidizes and degrades biofilms polysaccharides concomitantly producing stoichiometrically H2O2 as antibacterial agent. The enzymes will be coated on the catheters via a lubricant or by the Ultrasonic (US) process after their immobilization. Some novel CDH representatives already show very low activity on glucose which should be removed by further genetic engineering.
Consortium · 12 organisations
UNIVERSITAET FUER BODENKULTUR WIEN
AT · €405,402
PRONEFRO - PRODUTOS NEFROLOGICOS SA
PT · €164,240
TECHNISCHE UNIVERSITAET GRAZ
AT · €33,878
MULTIPROFILE HOSPITAL FOR ACTIVE TREATMENT AND EMERGENCY MEDECINE PIROGOV
BG · €123,960
UNIVERSITAET DUISBURG-ESSEN
DE · €276,000
OSM-DAN LTD
IL · €219,410
BAR ILAN UNIVERSITY
IL · €399,740
UNIVERSITAT POLITECNICA DE CATALUNYA
ES · €268,245
ASSOCIACAO UNIVERSIDADE EMPRESA PARA DESENVOLVIMENTO TECMINHO
PT · €280,800
SYNOVO GMBH
DE · €316,800
DEGANIA SILICONE LTD
IL · €182,700
DI DR ANDREAS PAAR KG
AT · €299,870
Research fields
← Find collaborators and more funded projects
Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.